Trials & Filings
-
Pfizer Terminates Two Phase III Programs
Pfizer is terminating Phase III development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD), following a review of the development and commercial portfolios in the Primary Care02.24.09
-
AZ, MAP Pharmaceuticals Phase III Asthma Study Misses Endpoints
MAP Pharmaceuticals initial Phase III trial of Unit Dose Budesonide (UDB) for the potential treatment of pediatric asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime symptom scores,02.24.09
